menu
    • menu
    [{"orgOrder":0,"company":"Westat","sponsor":"VITRAC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Westat \/ Westat","highestDevelopmentStatusID":"6","companyTruncated":"Westat \/ Westat"},{"orgOrder":0,"company":"Westat","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lamivudine","moa":"DNA | DNA polymerase\/reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"11","companyTruncated":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Westat","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University","highestDevelopmentStatusID":"11","companyTruncated":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Westat","sponsor":"TaiMed Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Westat \/ Westat","highestDevelopmentStatusID":"15","companyTruncated":"Westat \/ Westat"},{"orgOrder":0,"company":"Westat","sponsor":"TaiMed Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Westat \/ Westat","highestDevelopmentStatusID":"15","companyTruncated":"Westat \/ Westat"},{"orgOrder":0,"company":"Westat","sponsor":"TaiMed Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TMB-365","moa":"T-cell surface glycoprotein CD4 (CD4)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Westat \/ Westat","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ Westat"},{"orgOrder":0,"company":"Westat","sponsor":"Versiti | American National Red Cross | The Institute for Transfusion Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Westat \/ Versiti | American National Red Cross | The Institute for Transfusion Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Westat \/ Versiti | American National Red Cross | The Institute for Transfusion Medicine"},{"orgOrder":0,"company":"Westat","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PPV-23","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ Gansu Provincial Maternal and Child Health Care Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Westat

    Menu

    Westat

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline Hyclate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

                            Details : Doxycycline Hyclate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gonorrhea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Doxycycline Hyclate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIC-1911

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : VITRAC Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung C...

                            Details : VIC-1911 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 16, 2022

                            Lead Product(s) : VIC-1911

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : VITRAC Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : US Department of Defense | Clinipace Worldwide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

                            Details : Valproic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2020

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : US Department of Defense | Clinipace Worldwide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : US Department of Defense | Clinipace Worldwide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

                            Details : Valproic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2020

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : US Department of Defense | Clinipace Worldwide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : TaiMed Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

                            Details : TMB-365 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2019

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : TaiMed Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : TaiMed Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety of Trogarzoâ„¢ Administered as an Undiluted "IV Push" or an Intramuscular Injection

                            Details : Ibalizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 12, 2019

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : TaiMed Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PPV-23

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women

                            Details : PPV-23 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 23, 2016

                            Lead Product(s) : PPV-23

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : TaiMed Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

                            Details : Ibalizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 14, 2016

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : TaiMed Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Strategies to Reduce Iron Deficiency

                            Details : Ferrous Gluconate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            September 19, 2014

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin An...

                            Details : Lamivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 13, 2012

                            Lead Product(s) : Lamivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth